Home

YCANTH® speaker program

Model is for illustrative purposes only.

Register to hear from a clinical expert about how YCANTH can help patients in your office

YCANTH is the first FDA-approved, non-invasive, topical procedure that delivers treatment directly to molluscum lesions.1

All licensed healthcare professionals must be trained on the use and administration of YCANTH prior to use.

Upcoming sessions

Register to attend a speaker presentation to learn more about YCANTH
*Required field.

Thursday

September

19

7 PM ET

Natalia Biles,

Natalia Biles,

MD

Dermatologist

Annapolis, MD

Read Bio >

Thursday

October

3

7 PM ET

Natalia Biles,

Natalia Biles,

MD

Dermatologist

Annapolis, MD

Read Bio >

Thursday

October

24

7 PM ET

Natalia Biles,

Natalia Biles,

MD

Dermatologist

Annapolis, MD

Read Bio >
Click for additional sessions

Watch past speaker programs to learn more about YCANTH

Dr. Mercedes Gonzalez, MD, FAAD

Anthony Mancini, MD, FAAD, FAAP

Lisa Swanson, MD, FAAD

The opinions expressed within the video content are solely the speaker's and do not reflect the opinions and beliefs of Verrica Pharmaceuticals.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.

INDICATION

YCANTH (cantharidin) topical solution, 0.7% is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.
  • Local Skin Reactions: Reactions at the application site may occur, including vesiculation, pruritus, pain, discoloration, and erythema. Avoid application near eyes and mucosal tissue, and to healthy skin. If YCANTH contacts any unintended surface, or healthy skin, immediately remove. If severe local skin reactions occur, remove prior to the recommended 24 hours after treatment.
  • YCANTH is flammable, even after drying. Avoid fire, flame or smoking near lesion(s) during treatment and after application until removed.

ADVERSE REACTIONS:

The most common (incidence ≥1%) reactions are the following local skin reactions at the application site: vesiculation, pain, pruritus, scabbing, erythema, discoloration, application site dryness, edema, and erosion. Local skin reactions at the application site were observed in 97% of subjects treated with YCANTH during clinical trials. These local skin reactions are expected and related to the anticipated blistering response of the skin to cantharidin.

DRUG INTERACTIONS:

No studies evaluating the drug interaction potential of cantharidin have been conducted.

USE IN SPECIFIC POPULATIONS:

Pregnancy: There are no available data with use of YCANTH in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Given that systemic exposure to cantharidin following topical administration is low, maternal use is not expected to result in fetal exposure to the drug.

Lactation: Avoid application of YCANTH topical solution to areas with increased risk for potential ingestion by or ocular exposure to the breastfeeding child.

OVERDOSAGE:

Oral ingestion of cantharidin has resulted in renal failure, blistering and severe damage to the gastrointestinal tract, coagulopathy, seizures, and flaccid paralysis.

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Verrica Pharmaceuticals Inc. at 1-877-VERRICA (1-877-837-7422), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Local skin reactions are expected and should be reported if they are severe.

Reference: 1. Data on file. Verrica Pharmaceuticals Inc., 2024.

FDA=Food and Drug Administration.